Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Hira Rizvi"'
Autor:
Ian P. Winters, Charles M. Rudin, Hongchen Cai, Monte M. Winslow, Maryam Yousefi, Zoë N. Rogers, Chuan Li, Hira Rizvi, Christopher D. McFarland, Dmitri A. Petrov, Wen-Yang Lin
Publikováno v:
Cancer Research. 81:4570-4580
The lack of knowledge about the relationship between tumor genotypes and therapeutic responses remains one of the most critical gaps in enabling the effective use of cancer therapies. Here, we couple a multiplexed and quantitative experimental platfo
Autor:
Jennifer L. Sauter, Barry S. Taylor, Andrew J. Plodkowski, Mark T.A. Donoghue, Charles M. Rudin, Adam J. Schoenfeld, Peter Sawan, William D. Travis, Gregory J. Riely, Jacklynn V. Egger, Marc Ladanyi, Kathryn C. Arbour, Matthew D. Hellmann, Amanda Beras, Rocio Perez-Johnston, Natasha Rekhtman, Hira Rizvi, Chaitanya Bandlamudi
Publikováno v:
Ann Oncol
BACKGROUND: PD-L1 expression is the only FDA-approved biomarker for immune checkpoint inhibitors (ICIs) in patients with lung adenocarcinoma, but sensitivity is modest. Understanding the impact of molecular phenotype, clinical characteristics, and tu
Autor:
Andrew J. Plodkowski, Dung T. Le, Juan C. Osorio, Jennifer N. Durham, Hira Rizvi, Helena A. Yu, Michelle S. Ginsberg, Gregory J. Riely, Jamie E. Chaft, Luis A. Diaz, Peter Sawan, Joseph G. Crompton, Azadeh Namakydoust, Kathryn C. Arbour, Matthew D. Hellmann, Darragh Halpenny, Barzin Y. Nabet
Publikováno v:
J Clin Oncol
PURPOSE Response to programmed cell death protein 1 (PD-1) blockade is often conceptualized as resulting from reinvigoration of tumor-infiltrating lymphocytes. However, recruited antitumor immunity from the periphery may also be an important contribu
Autor:
Charles M. Rudin, Daniel K. Wells, Taha Merghoub, P. Manoj, Triparna Sen, H. J. Woo, Marissa Mattar, Jennifer L. Sauter, Joy A. Pai, Hira Rizvi, Mark T.A. Donoghue, Viola Allaj, Matthew D. Hellmann, Ansuman T. Satpathy, Jamie E. Chaft, Nisargbhai S. Shah, Helen Won, Andrew J. Plodkowski, Marina K. Baine, E. De Stanchina, Fathema Uddin, Brian Houck-Loomis, Álvaro Quintanal-Villalonga, Jedd D. Wolchok, Andrew Chow, Joseph M. Chan
Paired T cell receptor and RNA single cell sequencing (scTCR/RNA-seq) has allowed for enhanced resolution of clonal T cell dynamics in cancer. Here, we report a scTCR/RNA-seq dataset of 162,062 single T cells from 31 tissue regions, including tumor,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::972611c6bab01a045c5dec2909ec877c
https://doi.org/10.1101/2021.09.27.461389
https://doi.org/10.1101/2021.09.27.461389
Autor:
Dmitri A. Petrov, Maryam Yousefi, Hongchen Cai, Chuan Li, Wen-Yang Lin, Christopher D. McFarland, Charles M. Rudin, Zoë N. Rogers, Monte M. Winslow, Hira Rizvi, Ian P. Winters
Publikováno v:
Cancer research, vol 81, iss 17
The lack of knowledge about the relationship between tumor genotypes and therapeutic responses remains one of the most critical gaps in enabling the effective use of cancer therapies. Here, we couple a multiplexed and quantitative experimental platfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de845391e36fa1d9957ee0d8c6d536ed
https://escholarship.org/uc/item/5r96z9qc
https://escholarship.org/uc/item/5r96z9qc
Autor:
Nikolaus Schultz, Edward B. Garon, Maria E. Arcila, Michelle DeVeaux, Scott N. Gettinger, Zongzhi Liu, Katerina Politi, Christine A. Lydon, Anna Wurtz, Andrew J. Plodkowski, Gregory J. Riely, A. Truini, Hira Rizvi, J. Killam, Helena A. Yu, Wei Wei, Daniel Zelterman, Niamh Long, Isabel B. Oliva, Sarah B. Goldberg, Roy S. Herbst, Jungmin Choi, M. Ladanyi, Francisco Sanchez-Vega, Aaron Lisberg, Darragh Halpenny, Matthew D. Hellmann, Katherine Hastings, Guoping Cai, B.S. Henick, Mark M. Awad
Publikováno v:
Annals of Oncology
Background Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumor
Autor:
Zhiqin Huang, Pramod K. Srivastava, Song Liu, Jason A. Greenbaum, Dirk Jäger, Jiaqian Wang, Ognjen Milicevic, Willem-Jan Krebber, Barbara Schrörs, Sean Michael Boyle, Michal Bassani-Sternberg, Ana M. Mijalkovic Lazic, Amit A. Lugade, Kristen K. Dang, Han Si, Alessandro Sette, Jeffrey P. Ward, Irsan Kooi, Michael F. Princiotta, Begonya Comin-Anduix, Thierry Schuepbach, Pia Kvistborg, Julia Kodysh, William Chour, Vladimir B. Kovacevic, Jan H. Kessler, Ariella Sasson, Antoni Ribas, Brian Stevenson, Sriram Sridhar, Prateek Tanden, Robert D. Schreiber, Jason Perera, Kathleen C. F. Sheehan, Hira Rizvi, Sachet A. Shukla, Baikang Pei, Han Chang, Bo Li, Ion I. Mandoiu, Cristina Puig-Saus, Beatriz M. Carreno, Si Qiu, Jennifer M. Shelton, Patrick Jongeneel, Qiang Hu, Taha Merghoub, Matthew D. Hellmann, James P. Conway, Francisco Arcila, Ton N. Schumacher, Mathias Vormehr, Christopher A. Morehouse, Patrice Manning, Jonathon Blake, Pornpimol Charoentong, Angela Frentzen, Christopher A. Miller, Michael A. Kuziora, Bin Song, Lei Wei, Martin Löwer, Gabor Bartha, Justin Guinney, Niels Halama, Rolf Hilker, Yinong Sebastian, Veliborka Josipovic, Jason Harris, Geng Liu, Guilhem Richard, Arjun A. Rao, Nikola M. Skundric, Markus Mueller, Daniel K. Wells, Tatiana Shcheglova, Inka Zörnig, Weixuan Fu, John Sidney, Nadine Defranoux, Gabriela Steiner, Joseph D. Szustakowski, Arbel D. Tadmor, Maxim N. Artyomov, Jianmin Wang, George Coukos, Brandon W. Higgs, Milica R. Kojicic, Siranush Sarkizova, Daphne van Beek, Naibo Yang, Robert Ziman, Mignonette H. Macabali, Thomas Yu, Nicolas Guex, Nina Bhardwaj, Lorenzo F. Fanchi, Bjoern Peters, Christian Iseli, Song Wu, Maren Lang, Juliet Forman, Marit M. van Buuren, David Balli, Steven L. C. Ketelaars, Nir Hacohen, Ekaterina Esaulova, Maarten Slagter, Todd Creasy, Robert A. Petit, Yi-Hsiang Hsu, Ravi Gupta, Katie M. Campbell, Pascal Gellert, David Haussler, Jesse M. Zaretsky, Sofie R. Salama, Vanessa M. Hubbard-Lucey, Joel Greshock, Zeynep Kosaloglu Yalcin, Cornelis J. M. Melief, Priyanka Shah, Ioannis Xenarios, Nevena M. Ilic Raicevic, Andrew Lamb, Suchit Jhunjhunwala, Aly A. Khan, David Gfeller, James R. Heath, Richard Chen, Jia M. Chen, Alphonsus H. C. Ng, Elham Sherafat, Ana Belen Blazquez, Leo J. Lee, Beata Berent-Maoz, Cheryl Selinsky, Jasreet Hundal, Eduardo Cortes, Xengie Doan, Sahar Al Seesi, Adam Kolom, Fred Ramsdell, Nicolas Robine, Andrew J. Rech
Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches, and the param
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b788124c42a6ace5b9cb5efa2f3572c
https://resolver.caltech.edu/CaltechAUTHORS:20201019-121956456
https://resolver.caltech.edu/CaltechAUTHORS:20201019-121956456
Publikováno v:
Cureus
Coronavirus disease 2019 (COVID-19) continues to increase morbidity and mortality. Early recognition of symptoms, along with prompt intervention, is required to improve patient outcomes. COVID-19 can have a multifaceted presentation, which can be a d
Autor:
Andrew J. Plodkowski, Jia Luo, Biagio Ricciuti, Joao Victor Machado Alessi, Zihan Wei, Matthew D. Hellmann, Hira Rizvi, Mizuki Nishino, Mehmet Altan, Peter Sawan, Brett W. Carter, John V. Heymach, Mark M. Awad, Fangxin Hong, Elizabeth Jimenez-Aguilar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundPatients with non–small cell lung cancer (NSCLC) and a poor Eastern Cooperative Oncology Group Performance Status (ECOG PS) have been excluded from phase III immunotherapy clinical trials. We sought to evaluate clinical outcomes to first-
Autor:
Andrew J. Plodkowski, Darragh Halpenny, Jennifer L. Sauter, Barry S. Taylor, Ronglai Shen, Walid K. Chatila, Kurt A. Schalper, Kathryn C. Arbour, Matthew D. Hellmann, Ai Ni, Marc Ladanyi, Jedd D. Wolchok, Taha Merghoub, Philip Jonsson, Justin F. Gainor, Travis J. Hollmann, Natasha Rekhtman, David B. Solit, Konnor La, Mark G. Kris, Nikolaus Schultz, Michael F. Berger, Nicholas D. Socci, Jamie E. Chaft, Ahmet Zehir, Hira Rizvi, Alexandra Snyder, Gregory J. Riely, Niamh Long, Maria E. Arcila, Charles M. Rudin, Francisco Sanchez-Vega
Publikováno v:
Journal of Clinical Oncology. 36:633-641
Purpose Treatment of advanced non–small-cell lung cancer with immune checkpoint inhibitors (ICIs) is characterized by durable responses and improved survival in a subset of patients. Clinically available tools to optimize use of ICIs and understand